Thrombocytopenia with Tedizolid and Linezolid-Reference-Cited by-同舟云学术

Thrombocytopenia with Tedizolid and Linezolid

Published:2018-01 Issue:1 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lee Erica Yookyung¹,Caffrey Aisling R.¹²³

Affiliation:

1. University of Rhode Island, College of Pharmacy, Kingston, Rhode Island, USA

2. Veterans Affairs Medical Center, Infectious Diseases Research Program and Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA

3. Brown University, School of Public Health, Providence, Rhode Island, USA

Abstract

ABSTRACT Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we observed significantly increased risks of thrombocytopenia of similar magnitudes with both antibiotics: linezolid reporting odds ratio [ROR], 37.9 (95% confidence interval [CI], 20.78 to 69.17); tedizolid ROR, 34.0 (95% CI, 4.67 to 247.30).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01453-17

Reference19 articles.

1. Pfizer Inc. 2013. Zyvox package insert. Pfizer Inc., New York, NY.

2. Cubist Pharmaceuticals. 2014. Sivextro (tedizolid phosphate) package insert. Cubist Pharmaceuticals US, Lexington, MA.

3. Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials

4. U.S. Food and Drug Administration. 2017. FDA adverse event reporting system (FAERS). U.S. Food and Drug Administration, Silver Spring (MD). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm Accessed 21 February 2017.

5. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro activity of tedizolid against 43 species of Nocardia species;Scientific Reports;2024-03-04

2. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database;Frontiers in Pharmacology;2024-02-16

3. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects;Antimicrobial Agents and Chemotherapy;2023-11-15

4. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians;Pharmaceuticals;2023-09-15

5. Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients;Infection and Drug Resistance;2023-09